Anti-PLVAP / PV-1 Antibody [MECA-32] (A281087)

Anti-PLVAP / PV-1 Antibody [MECA-32]

Rat monoclonal [MECA-32] antibody to PLVAP / PV-1.

This antibody recognises mouse plasmalemma vesicle-associated protein (PLVAP), a ~60 kDa protein also known as MECA-32 and PV-1. PLVAP is a transmembrane homodimer associated with endothelial cell caveolae and fenestrae. In adult and embryonic mice, PLVAP is primarily expressed on endothelial tissues but shows restricted distribution in skeletal, cardiac and brain tissues. In embryonic mice, PLVAP expression, on the vasculature associated with blood brain barrier has been reported to be developmentally regulated.In humans, PLVAP is selectively up-regulated in a variety of high-grade brain tumors, including glioblastoma and metastatic carcinoma, as well as other cerebral disorders associated with blood-brain barrier disruption, such as acute ischemia. PLVAP represents a novel marker of brain tumour angiogenesis and integrity of the blood-brain barrier and is a potential therapeutic target.

IHC-Fr: 1:25 - 1:100, Use 10µl of the suggested working dilution to label 1x10⁶ cells in 100µl.

Mouse

Rat

Monoclonal

MECA-32

IgG2a

1 mg/ml

Liquid

Supplied in Phosphate Buffered Saline with 0.09% Sodium Azide.

Shipped at ambient temperature. Upon delivery aliquot and store at -20°C. When thawed, aliquot the sample as needed. Short term (up to 4 weeks): store at 4°C. Long term: store at -20°C. Avoid freeze / thaw cycles. Storage in frost free freezers is not recommended.

Rat anti Mouse PLVAP antibody, clone MECA-32 recognizes murine plasmalemma vesicle-associated protein (PLVAP), a ~60 kDa protein also known as MECA-32 and PV-1. PLVAP is a transmembrane homodimer associated with endothelial cell caveolae and fenestrae. In adult and embryonic mice, PLVAP is primarily expressed on endothelial tissues but shows restricted distribution in skeletal, cardiac and brain tissues. In embryonic mice, PLVAP expression, on the vasculature associated with blood brain barrier has been reported to be developmentally regulated.In humans, PLVAP is selectively up-regulated in a variety of high-grade brain tumors, including glioblastoma and metastatic carcinoma, as well as other cerebral disorders associated with blood-brain barrier disruption, such as acute ischemia. PLVAP represents a novel marker of brain tumour angiogenesis and integrity of the blood-brain barrier and is a potential therapeutic target.